- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05504083
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
March 6, 2024 updated by: InventisBio Co., Ltd
A Multicenter Randomized and Controlled Phase IIb Study to Evaluate the Efficacy and Safety of D-0120 Tablets in Patients With Primary Hyperuricemia
This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
121
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nan Tang
- Phone Number: 13581714593
- Email: nancy.tang@sanofi.com
Study Locations
-
-
-
Baotou, China
- Not yet recruiting
- Inner Mongolia Baogang Hospital
-
Beijing, China
- Not yet recruiting
- Peking Union Medical College Hospital
-
Beijing, China
- Not yet recruiting
- Beijing Chao-Yang Hospital, Capital Medical University
-
Changchun, China
- Not yet recruiting
- The First Hospital of Jilin University
-
Changzhou, China
- Not yet recruiting
- The First People's Hospital Of Changzhou
-
Foshan, China
- Not yet recruiting
- Foshan Nanhai People's Hospital
-
Guangzhou, China
- Not yet recruiting
- Zhujiang Hospital of Southern Medical University
-
Guangzhou, China
- Not yet recruiting
- Nanfang Hospital
-
Guangzhou, China
- Not yet recruiting
- Guangzhou First People's Hospital
-
Guangzhou, China
- Not yet recruiting
- The Second People's Hospital of Guangdong Province
-
Hengyang, China
- Recruiting
- The First Affiliated Hospital of University of South China
-
Huzhou, China
- Not yet recruiting
- Huzhou third people's Hospital
-
Kunming, China
- Not yet recruiting
- First Affiliated Hospital of Kunming Medical University
-
Luoyang, China
- Not yet recruiting
- The First Affiliated Hospital of Henan University of Science and Technology
-
Nanchong, China
- Not yet recruiting
- Affiliated Hospital of North Sichuan Medical College
-
Nanjing, China
- Not yet recruiting
- Zhongda Hospital Southeast University
-
Nanjing, China
- Not yet recruiting
- Gulou Hospital Affiliated to Nanjing University Gulou Hospital Affiliated to Nanjing University
-
Nantong, China
- Not yet recruiting
- Affiliated Hospital of Nantong University
-
Ningbo, China
- Not yet recruiting
- Ningbo Huamei Hospital, University of Chinese Academy of Sciences
-
Shanghai, China
- Not yet recruiting
- Changhai Hospital of Shanghai
-
Xi'an, China
- Not yet recruiting
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Xining, China
- Not yet recruiting
- Qinghai Province People's Hospital
-
Zhengzhou, China
- Not yet recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Zigong, China
- Not yet recruiting
- Zigong Fourth People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;
Subject who meets one of the following criteria:
i. History of gout attack: Meeting 2015 ACR/EULAR Gout Classification Criteria and fasting serum uric acid ≥ 480 μmol/L at screening (local laboratory of study site) ii. For asymptomatic hyperuricemia, it is acceptable to meet either of the two criteria:
- Serum uric acid ≥ 420 μmol/L for at least 3 months (subject to hospital medical record or test report), diagnosis with hyperuricemia before screening, and fasting serum uric acid at screening ≥ 540 μmol/L (local laboratory of study site);
- Serum uric acid ≥ 420 μmol/L for at least 3 months (subject to hospital medical record or test report), diagnosis with hyperuricemia before screening, and fasting serum uric acid at screening ≥ 480 μmol/L (local laboratory of study site), with concomitant primary hypertension or primary hyperlipidemia or type 2 diabetes mellitus, which is treated with a stable dose of antihypertensive or lipid-lowering or hypoglycemic treatment for at least 3 months;
- At screening, 18.0 kg/m2 ≤ body mass index (BMI) ≤ 32.0 kg/m2;
- Hematology, Blood chemistry and Urinalysis examination were basically normal.
Exclusion Criteria:
- Prior intolerance to benzbromarone or contraindication to medication;
- Secondary hyperuricemia caused by tumor, chronic kidney disease, blood disease or drugs, etc.;
- Arthropathy caused by arthritis rheumatoid, purulent arthritis, traumatic arthritis, psoriatic arthritis, pseudogout or systemic lupus erythematosus, etc.;
- Arthropathy caused by chemotherapy, radiotherapy or chronic lead poisoning;
- Urinary calculi confirmed by B-ultrasound during screening period;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: D-0120 group 1
take D-0120 dose 1 orally during the treatment period.
|
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Part B: Subjects will be assigned to D-0120 group 3.
|
Experimental: D-0120 group 2
take D-0120 dose 2 orally during the treatment period.
|
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Part B: Subjects will be assigned to D-0120 group 3.
|
Active Comparator: Benzbromarone
take benzbromarone orally during the treatment period.
|
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
|
Experimental: D-0120 group 3
take D-0120 dose 3 orally during the treatment period.
|
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Part B: Subjects will be assigned to D-0120 group 3.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with serum uric acid ≤ 360 μmol/L
Time Frame: Day 1 - Day 85
|
Percentage of subjects with serum uric acid ≤ 360 μmol/L at week 12 of treatment - based on test results by the central lab.
|
Day 1 - Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with serum uric acid≤ 360 μmol/L
Time Frame: Day 1 -Day 56
|
Percentage of subjects with serum uric acid ≤ 360 μmol/L at weeks 4 and 8 of treatment - based on test results by the central lab;
|
Day 1 -Day 56
|
Changes in serum uric acid
Time Frame: Day 1 - Day 85
|
Changes in serum uric acid from baseline at weeks 4, 8 and 12 of treatment - based on test results by the central lab;
|
Day 1 - Day 85
|
Change percentage in serum uric acid
Time Frame: Day 1 - Day 85
|
Change percentage in serum uric acid from baseline at weeks 4, 8 and 12 of treatment - based on test results by the central lab.
|
Day 1 - Day 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiaofeng Zeng, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 28, 2022
Primary Completion (Estimated)
April 5, 2024
Study Completion (Estimated)
April 26, 2024
Study Registration Dates
First Submitted
August 11, 2022
First Submitted That Met QC Criteria
August 14, 2022
First Posted (Actual)
August 17, 2022
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0120-206
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperuricemia
-
Lingling Yu (103250)Wuhan Integrated Traditional Chinese and Western Medicine Hospital; Xianning...Recruiting
-
Shanghai Institute Of Biological ProductsFirst Affiliated Hospital Bengbu Medical CollegeCompletedAsymptomatic HyperuricemiaChina
-
China Medical University HospitalUnknown"Hyperuricemia,Anserine"Taiwan
-
Sun Yat-sen UniversityRecruiting
-
China Medical University HospitalUnknownHyperuricemia, Anserine, PharmacokineticTaiwan
-
Hebei Medical UniversityCompletedHeart Failure, HyperuricemiaChina
-
AstraZenecaContract Research Organization: USA; PAREXEL Early Phase Clinical Unit Baltimore and other collaboratorsCompletedAsymptomatic HyperuricemiaUnited States
-
University of MinnesotaCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
Clinical Trials on D-0120
-
InventisBio Co., LtdCompleted
-
InventisBio Co., LtdCompletedHealthy VolunteersUnited States
-
InventisBio Co., LtdRecruiting
-
Indonesia UniversityPT Paragon Technology and InnovationCompleted
-
InventisBio Co., LtdCompleted
-
Lee's Pharmaceutical LimitedUnknownOvarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerChina
-
Rhode Island HospitalVirtually Better, Inc.CompletedMental Health | Human Immunodeficiency VirusUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted